Literature DB >> 12758175

A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism.

Koichi Takayama1, Paul N Reynolds, Joshua J Short, Yosuke Kawakami, Yasuo Adachi, Joel N Glasgow, Marianne G Rots, Victor Krasnykh, Joanne T Douglas, David T Curiel.   

Abstract

The efficiency of cancer gene therapy with recombinant adenoviruses based on serotype 5 (Ad5) has been limited partly because of variable, and often low, expression by human primary cancer cells of the primary cellular-receptor which recognizes the knob domain of the fiber protein, the coxsackie and adenovirus receptor (CAR). As a means of circumventing CAR deficiency, Ad vectors have been retargeted by utilizing chimeric fibers possessing knob domains of alternate Ad serotypes. We have reported that ovarian cancer cells possess a primary receptor for Ad3 to which the Ad3 knob binds independently of the CAR-Ad5 knob interaction. Furthermore, an Ad5-based chimeric vector, designated Ad5/3, containing a chimeric fiber proteins possessing the Ad3 knob, demonstrates CAR-independent tropism by virtue of targeting the Ad3 receptor. Based on these findings, we hypothesized that a mosaic virus possessing both the Ad5 knob and the Ad3 knob on the same virion could utilize either primary receptor, resulting in expanded tropism. In this study, we generated a dual-knob mosaic virus by coinfection of 293 cells with Ad5-based and Ad5/3-based vectors. Characterization of the resultant virions confirmed the incorporation of both Ad5 and Ad3 knobs in the same particle. Furthermore, this mosaic virus was able to utilize either receptor, CAR and the Ad3 receptor, for virus attachment to cells. Enhanced Ad infectivity with the mosaic virus was shown in a panel of cell lines, with receptor profiles ranging from CAR-dominant to Ad3 receptor-dominant. Thus, this mosaic virus strategy may offer the potential to improve Ad-based gene therapy approaches by infectivity enhancement and tropism expansion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12758175     DOI: 10.1016/s0042-6822(03)00067-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

Review 1.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

Review 2.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

3.  Outbreak of acute respiratory infection among infants in Lisbon, Portugal, caused by human adenovirus serotype 3 and a new 7/3 recombinant strain.

Authors:  Helena Rebelo-de-Andrade; Cristiana Pereira; Marta Gíria; Ema Prudêncio; Maria João Brito; Etelvina Calé; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2010-02-10       Impact factor: 5.948

4.  Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.

Authors:  Zeng B Zhu; Sharmila K Makhija; Baogen Lu; Minghui Wang; Shuyi Wang; Koichi Takayama; Gene P Siegal; Paul N Reynolds; David T Curiel
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

5.  Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: implications for gene therapy and vaccine vector development.

Authors:  Anjan Purkayastha; Susan E Ditty; Jing Su; John McGraw; Ted L Hadfield; Clark Tibbetts; Donald Seto
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus.

Authors:  Ophélia Granio; Marine Porcherot; Stéphanie Corjon; Kuntida Kitidee; Petra Henning; Assia Eljaafari; Andrea Cimarelli; Leif Lindholm; Pierre Miossec; Pierre Boulanger; Saw-See Hong
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

Review 7.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

Review 8.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

Review 9.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

10.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.